Products Categories
  • Ms.Haylee
    Tel: 18061870061

  • Mobile:18061870061
  • Tel:18061870061
  • Fax:
  • URL:https://eubo.en.alibaba.com
  • Province/state:
  • City:
  • Street:No. 18, Huashan Road, Xinbei District, Changzhou, Jiangsu, China (Mainland)
  • MaxCard:
Home > Products >  Pharmaceutical Grade Prasugrel Raw Material Powder CAS 150322-43-3 Prasugrel

Pharmaceutical Grade Prasugrel Raw Material Powder CAS 150322-43-3 Prasugrel CAS NO.150322-43-3

  • Min.Order: 0
  • Payment Terms:
  • Product Details

Keywords

  • Prasugrel
  • Prasugrel powder
  • 150322-43-3

Quick Details

  • ProName: Pharmaceutical Grade Prasugrel Raw Mat...
  • CasNo: 150322-43-3
  • Molecular Formula: C20H20FNO3S
  • Appearance: White powder
  • Application: Prasugrel is used in combination with ...
  • DeliveryTime: Abiut 10 days
  • PackAge: Aluminum foil bag,fluorinated bottles,...
  • Port: Shenzhen port
  • Purity: 99%
  • Storage: Store in cool & dry place. Keep away f...
  • Transportation: 1) Door to Door Service by DHL/FEDEX/E...
  • LimitNum: 0
  • Moisture Content: <0.1%
  • Impurity: <0.1%

Superiority

1) Provide costomers with "one-stop"packaging service,from research,development,production,export and so on.
2) We have our own R&D and production base,equipped with advanced production equipment and precision testing the Unitef States Pharmacopoeia(USP),the Britis Pharmacopoeia(EP) and other international advanced standards.All products are through the KOSGER,HALAL certification,the ISO quality management system certification and the HACCP certification.
3) More than 12 years of export experience.
4)Competitive price in China market.

Details

Prasugrel (trade name Effient in the US and India, and Efient in the EU) is a pharmaceutical drug that acts as a platelet inhibitor and is used to prevent thrombosis (blood clotting). It was developed by Daiichi Sankyo Co. and produced by Ube and currently marketed in the United States in cooperation with Eli Lilly and Company.
Prasugrel was approved for use in Europe in February 2009, and in the US in July 2009, for the reduction of thrombotic cardiovascular events (including stent thrombosis) in people with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI).

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog